Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC)

Full text
Author(s):
Alves-Fernandes, Debora Kristina [1] ; de Oliveir, Erica Aparecida [1] ; Faiao-Flores, Fernanda [1, 2] ; Alicea-Rebecca, Gretchen [3] ; Weeraratna, Ashani T. [3] ; Smalley, Keiran S. M. [2] ; de Moraes Barros, Silvia Berlanga [1] ; Maria-Engler, Silvya Stuchi [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol, Skin Biol & Melanoma Lab, 580 Prof Lineu Prestes Ave, BR-05508000 Sao Paulo - Brazil
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, 12902 Magnolia Dr, Tampa, FL - USA
[3] Wistar Inst Anat & Biol, Melanoma Res Ctr, Immunol Microenvironm & Metastasis, 3601 Spruce St, Philadelphia, PA 19104 - USA
Total Affiliations: 3
Document type: Journal article
Source: PHARMACOLOGICAL RESEARCH; v. 141, p. 63-72, MAR 2019.
Web of Science Citations: 1
Abstract

Melanoma accounts for only 4% of malignant neoplasms of the skin, but is considered the most serious because it is highly deadly. Mutations in the MAPK (Ras-Raf-MEK-ERK) pathway is closely linked to the lack of control of cell proliferation. Especially in melanoma, this pathway has become a target for the development of oncogene-targeted therapies, such as the potent inhibitors of v-Raf murine sarcoma viral oncogene homolog B (BRAFi) and mitogen-activated protein kinase kinase (MEKi). Very high rates of response have been achieved, but most patients are relapsed due to the development of resistance, justifying the constant search for new therapeutic compounds. Early results from our group indicated that 4-nerolidylcatechol (4-NC), a catechol compound extracted from Pothomorphe umbellata, induces DNA damage, ROS production, increased p53 expression culminating in apoptosis in melanoma but with no data regarding the 4-NC effects in cells resistant to BRAFi or MEKi. Therefore, here we evaluated the role of 4-NC alone or in combination with BRAFi/MEKi in resistant melanoma cells. Double-resistant cells were generated and characterized by MAPK pathway reactivation. 4-NC alone or in combination (30 mu M) with MAPK inhibitors was cytotoxic, inhibited colony formation and decreased invasiveness in two and three-dimensional cell culture models of treatment-naive, BRAFi-resistant and BRAF/MEKi double-resistant melanoma cells. Apoptosis induction was demonstrated in resistant and double-resistant melanoma cell lines after 4-NC treatments. 4-NC showed important ability to induce apoptosis via Endoplasmatic Reticulum (ER) stress and specifically BiP and CHOP that had increased protein expression in all melanoma cell lines proving to be part of the ER stress pathway activation. CHOP knockdown slightly but enough increases cellular viability following 4-NC treatment indicating that apoptosis observed is partially dependent on CHOP. In summary, we show that 4-NC is a compound with activity against cutaneous melanoma, including resistant cells to clinically approved therapies. (AU)

FAPESP's process: 17/07010-2 - Effect of the aged-related changes in tumor microenvironment in the angiogenesis and lymphangiogenesis
Grantee:Débora Kristina Alves Fernandes
Support type: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 14/24400-0 - In vitro models for pre clinical studies of melanoma Chemoresistant
Grantee:Silvya Stuchi Maria-Engler
Support type: Regular Research Grants
FAPESP's process: 14/06959-0 - Evaluation of the potential for overcoming melanoma chemoresistance to BRAF V600E (Vemurafenib) and MEK (Trametinib) inhibitors using combined therapy with 4-nerolidylcatechol (4-NC)
Grantee:Débora Kristina Alves Fernandes
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 17/04926-6 - Melanoma and chemoresistance: in vitro and in silico models to exploit therapeutic targets
Grantee:Silvya Stuchi Maria-Engler
Support type: Research Projects - Thematic Grants